Holen Sie sich die Stockscreener-App
1.78
14.01%
-0.29
Handel nachbörslich:
1.78
Nextcure Inc Aktie (NXTC) Neueste Nachrichten
NXTCNextcure Inc Options - Finviz
NextCure Inc. (NXTC) Q1 2026 Earnings: EPS Beat Mitigates Losses Amid Ongoing Clinical DevelopmentEarnings Forecast Report - dars.gov.et
NextCure, Inc.(NasdaqGS: NXTC) added to Russell Microcap Value Benchmark Index - marketscreener.com
NextCure, Inc.(NasdaqGS: NXTC) added to Russell 3000E Index - marketscreener.com
NextCure, Inc.(NasdaqGS: NXTC) added to Russell Microcap Index - marketscreener.com
Price to book forward of NextCure, Inc. – NASDAQ:NXTC - TradingView
Enterprise value to EBIT forward of NextCure, Inc. – NASDAQ:NXTC - TradingView
NextCure, Inc. Actuals & Estimates (NASDAQ:NXTC) - TradingView
NextCure, Inc. Actuals & Estimates (FWB:2US0) - TradingView
NextCure Inc (NXTC) Valuation: PE, PB & Fair Value Analysis - TradingKey
NXTC Forecast — Price Target — Prediction for 2027 - TradingView
NextCure, Inc. Actuals & Estimates (BOATS:NXTC) - TradingView
2US0 Forecast — Price Target — Prediction for 2027 - TradingView
What's going on with NextCure stock Wednesday? - MSN
NextCure Shareholders Approve Expanded Omnibus Incentive Plan - TipRanks
NextCure (NASDAQ: NXTC) shareholders back amended 2019 incentive plan and director slate - Stock Titan
NextCure Inc (NXTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NextCure (NXTC) director receives 2,340 options at $2.02 strike - Stock Titan
Director at NextCure (NASDAQ: NXTC) granted 2,340 stock options - Stock Titan
NextCure (NXTC) director awarded 2,340 options at $2.02 exercise price - Stock Titan
NextCure (NXTC) director receives grant of 2,340 stock options at $2.02 - Stock Titan
NextCure (NXTC) director awarded options for 2,340 shares at $2.02 - Stock Titan
NextCure (NASDAQ: NXTC) director receives stock options grant for 3,510 shares - Stock Titan
NextCure Stocklong-term oncology model under scrutiny - AD HOC NEWS
NextCure Inc (NXTC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NextCure (NXTC) AGM 2026 Summary - Quartr
NextCure Inc (NXTC) Institutional Confidence - TradingKey
NextCure Inc (NXTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NextCure Inc (NXTC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NXTC | NextCure, Inc. Common Stock Insider Trading - Quiver Quantitative
NextCure Inc (NXTC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NextCure Inc (NXTC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NextCure Inc (NXTC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NextCure Inc. (NXTC) Q1 2026 Earnings: Narrower Loss Beats Estimates, but Zero Revenue Weighs on SharesNet Income Trends - dars.gov.et
NXTC Q1 2026 Earnings: Narrower Loss Beats Estimates, No Revenue YetEarnings Decline Risk - newsline.com
Experimental drug shrinks tumors in hard-to-treat cancers - Rare Cancer News
NextCure Inc stock (US65343E1082): Pipeline focus after restructuring and cash runway update - AD HOC NEWS
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers - The Manila Times
Cancer experts discuss SIM0505 trial data in on-demand replay - Stock Titan
NextCure Inc. (NXTC) Q1 2026 Earnings: EPS Beat Driven by Lower Operating Costs, Stock Falls on Cash Runway ConcernsRevenue Warning Signal - newsline.com
What's Going On With NextCure Stock Wednesday? - Benzinga
NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous CarcinomaSlideshow (NASDAQ:NXTC) 2026-06-02 - Seeking Alpha
Lucid Capital Maintains NextCure(NXTC.US) With Buy Rating, Maintains Target Price $25 - Moomoo
NextCure Reports 55% Response Rate in Phase 1 SIM0505 Trial for Gynecologic Cancers at ASCO 2026 - Minichart
NextCure Reports Positive SIM0505 Phase 1 Gynecologic Cancer Data - TipRanks
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026 - The Manila Times
NextCure presents SIM0505 Phase 1 data: 55% ORR in gynecologic cancers; cash runway into Q1 2027 - TradingView
NextCure reports 55% response rate for SIM0505 in gynecologic cancers - Investing.com
Strong SIM0505 Phase 1 gynecologic cancer data for NextCure (Nasdaq: NXTC) - Stock Titan
Experimental ovarian and uterine cancer drug shows 55% response rate - Stock Titan
NXTC Q1 2026 Earnings: Narrower-Than-Expected Loss Driven by Cost DisciplineProfitability Analysis - The Legal Advocate
NextCure Inc. (NXTC) Surges 5.44% as Shares Test Key ResistanceGap Up Stocks - The Legal Advocate
NXTC Q1 2026 Earnings: Narrowed Loss Beats Estimates, Stock GainsEarnings Yield Spread - newsline.com
1.18%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):